logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
S

Shu, Yongqian

Nanjing Medical University
H指数:0
被引数:1

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non-Small Cell Lung for Cancer: a Multicenter Phase I/II Study
CLINICAL CANCER RESEARCH
IF10.2
2022-03-1417
OAAI
Zhou, Qing; Wu, Lin; Hu, Pei; An, Tongtong; Zhou, Jianying; Zhang, Li; Liu, Xiao-Qing; Luo, Feng; Zheng, Xin; Cheng, Ying; Yang, Nong; Li, Junling; Feng, Jifeng; Han, Baohui; Song, Yong; Wang, Kai; Fang, Jian; Zhao, Hong; Shu, Yongqian; Lin, Xiao-Yan; Chen, Zhihong; Gan, Bin; Xu, Wan-Hong; Tang, Wei; Zhang, Xiaoying; Yang, Jin-Ji; Xu, Xiao; Wu, Yi-Long
Consensus for HER2 alterations testing in non-small-cell lung cancer

非小细胞肺癌HER2改变检测共识

ESMO OPEN
IF8.3
2022-02-0166
OAAI
Ren, S.; Wang, J.; Ying, J.; Mitsudomi, T.; Lee, D. H.; Wang, Z.; Chu, Q.; Mack, P. C.; Cheng, Y.; Duan, J.; Fan, Y.; Han, B.; Hui, Z.; Liu, A.; Liu, J.; Lu, Y.; Ma, Z.; Shi, M.; Shu, Y.; Song, Q.; Song, X.; Song, Y.; Wang, C.; Wang, X.; Wang, Z.; Xu, Y.; Yao, Y.; Zhang, L.; Zhao, M.; Zhu, B.; Zhang, J.; Zhou, C.; Hirsch, F. R.
Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes

胆道癌的基因组改变可预测预后和免疫治疗结果

JOURNAL FOR IMMUNOTHERAPY OF CANCER
IF10.6
2021-11-1837
OAAI
Chen, Xiaofeng; Wang, Deqiang; Liu, Jing; Qiu, Jingrong; Zhou, Jun; Ying, Jieer; Shi, Yan; Wang, Zhaoxia; Lou, Haizhou; Cui, Jiuwei; Zhang, Jingdong; Liu, Yunpeng; Zhao, Fengjiao; Pan, Lanlan; Zhao, Jianyi; Zhu, Dongqin; Chen, Shiqing; Li, Xiangcheng; Li, Xue; Zhu, Liuqing; Shao, Yang; Shu, Yongqian
Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study

新型anti-HER2治疗性抗体RC48在HER2-overexpressing，局部晚期或转移性胃或胃食管交界处癌患者中的疗效和安全性: 一项单臂II期研究

CANCER COMMUNICATIONS
IF24.9
2021-10-19116
OAAI
Peng, Zhi; Liu, Tianshu; Wei, Jia; Wang, Airong; He, Yifu; Yang, Liuzhong; Zhang, Xizhi; Fan, Nanfeng; Luo, Suxia; Li, Zhen; Gu, Kangsheng; Lu, Jianwei; Xu, Jianming; Fan, Qingxia; Xu, Ruihua; Zhang, Liangming; Li, Enxiao; Sun, Yuping; Yu, Guohua; Bai, Chunmei; Liu, Yong; Zeng, Jiangzheng; Ying, Jieer; Liang, Xinjun; Xu, Nong; Gao, Chao; Shu, Yongqian; Ma, Dong; Dai, Guanghai; Li, Shengmian; Deng, Ting; Cui, Yuehong; Fang, Jianmin; Ba, Yi; Shen, Lin
Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial
CANCER COMMUNICATIONS
IF24.9
2021-06-2918
OAAI
Shi, Yuankai; Lei, Kaijian; Jia, Yuming; Ni, Bingqiang; He, Zhiyong; Bi, Minghong; Wang, Xicheng; Shi, Jianhua; Zhou, Ming; Sun, Qian; Wang, Guolei; Chen, Dongji; Shu, Yongqian; Liu, Lianke; Guo, Zhongliang; Liu, Yong; Yang, Junquan; Wang, Ke; Xiao, Ke; Wu, Lin; Yi, Tienan; Sun, Debin; Kang, Mafei; Ma, Tianjiang; Mao, Yimin; Shi, Jinsheng; Tang, Tiegang; Wang, Yan; Xing, Puyuan; Lv, Dongqing; Liao, Wangjun; Luo, Zhiguo; Wang, Bin; Wu, Xiaohong; Zhu, Xiaoli; Han, Shuhua; Guo, Qisen; Liu, Rongyu; Lu, Zhiwei; Zhang, Jianyong; Fang, Jian; Hu, Changlu; Ji, Yinghua; Liu, Guolong; Lu, Hong; Wu, Dedong; Zhang, Junhong; Zhu, Shuyang; Liu, Zheng; Qiu, Wensheng; Ye, Feng; Yu, Yan; Zhao, Yanqiu; Zheng, Qinhong; Chen, Jun; Pan, Zhanyu; Zhang, Yiping; Lian, Wenjuan; Jiang, Bo; Qiu, Bo; Zhang, Guojun; Zhang, Hua; Chen, Yanju; Chen, Yuan; Duan, Hongbing; Li, Manxiang; Liu, Shengming; Ma, Lijun; Pan, Hongming; Yuan, Xia; Yuan, Xueli; Zheng, Yulong; Gao, Emei; Zhao, Li; Wang, Shumin; Wu, Can
Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial

Camrelizumab联合吉西他滨和奥沙利铂 (GEMOX) 治疗晚期胆道癌患者: 单臂，开放标签，II期试验

JOURNAL FOR IMMUNOTHERAPY OF CANCER
IF10.6
2020-11-10112
OAAI
Chen, Xiaofeng; Wu, Xiaofeng; Wu, Hao; Gu, Yanhong; Shao, Yang; Shao, Qianwen; Zhu, Feipeng; Li, Xiao; Qian, Xiaofeng; Hu, Jun; Zhao, Fengjiao; Mao, Weidong; Sun, Jing; Wang, Jian; Han, Gaohua; Li, Changxian; Xia, Yongxiang; Seesaha, Poshita Kumari; Zhu, Dongqin; Li, Huajun; Zhang, Junling; Wang, Guoqiang; Wang, Xuehao; Li, Xiangcheng; Shu, Yongqian

研究方向

暂未获取到该数据
P
Pei Ma
H 指数:38论文数:141被引数:6,607
T
Tongpeng Xu
H 指数:37论文数:104被引数:6,291
R
Rui Xia
H 指数:43论文数:143被引数:7,799
W
Wenming Chen
H 指数:31论文数:138被引数:4,273
张二宝 封面图
张二宝
H 指数:47论文数:178被引数:8,341
T
Tao Yu
H 指数:22论文数:48被引数:5,854
M
Ming Sun
H 指数:54论文数:153被引数:1.3万
M
Mingde Huang
H 指数:18论文数:56被引数:2,100
Y
Yanhong Gu
H 指数:37论文数:157被引数:4,366
魏德 封面图
魏德
H 指数:65论文数:236被引数:1.3万